MDoutlook ASCO Conference Research Analysis Resets Client’s Portfolio Commercialization Strategy

“We attend ASCO regularly and never knew we could get help in ensuring the presented clinical data was optimally received by oncologists or how competitive announcements could potentially have an adverse impact. MDoutlook gave us new insights into projected usage rates of our therapy and helped us recalibrate our market share targets in the major global markets we operate in.”

-Major Global Biopharma Organization with Growing Oncology Portfolio

MDoutlook assists pharma and life sciences organizations in maximizing results at major industry conferences, and achieved demonstrable success for one client at 2016 ASCO.

Client Need:
A major international pharma company with a growing oncology portfolio was ready to make a significant data announcement about a new treatment in dual checkpoint inhibitor antibodies in SCLC. They needed an impact assessment of current treatments as well as other data announcements scheduled for the category at the conference.

Project Delivered:
In only 4 weeks, MDoutlook turned around an integrated global research study of live panel discussions and a survey of pre-screened oncologists and physicians in multiple disciplines with high patient volumes, specialized knowledge and experience with SCLC treatments in the US, and key EU and international markets.

Results Achieved:
As a result, we provided immediate, actionable insights on how current treatments and new data developments at ASCO in the SCLC category would affect this company’s announcements about its new therapy entrant in the space. Based on our analysis and report, the company was able to project future physician usage of its treatment around the world and better calibrate market share growth globally of its treatment versus competitor treatments over time.

Give us the opportunity to deliver the same results for you before your next cancer conference by contacting the team at MDoutlook today.
We offer custom and syndicated programs for ASCO, EHA, ESMO and ASH, and custom research at many other cancer conferences.

Slide 16 PictureSlide 17 Picture

Oncology Conference Insights and the IMPACT of Data Announcements

Are you getting the most out of industry events?

MDoutlook leverages its client-acclaimed oncology insights and intelligence to drive our clients’ commercialization success.

We work with our clients to understand the impact of data announcements made at global conferences and assess the awareness and impact of these announcements on treatment utilization. We focus on important aspects, including meeting attendance and knowledge of the presented data to provide actionable and relevant insights for the market. Our response targeting allows us to create subgroup insights to maximize findings and project the impact at these conferences, such as ASCO, ESMO, ASH, and SABCS.

Examples of MDoutlook’s Oncology Conference Insights include, but are not limited to:

•Immediate clinical impact of data announcements in the form of robust and projectable quantitative market share analysis and insights into future treatment decisions
•Stratifying channel impact of announcements between attendees and non-attendees (i.e. significance of learning about new data at the meeting vs. via the news media)
•Pre-/onsite-/post- conference polling that includes providing a very quick read-out; identifying and vetting the right respondents; and querying robust sample sizes
•Focusing on disease-specific coverage and regional impact assessment

Take the guesswork out of your oncologist insights research and contact the team at MDoutlook today.

ASCO 2018